Log In or Create Account

CROI
Conference on Bacteriophages
RWHAP Clinical Conference
Podcasts
Key Slides
Question of the Week
Donate
Contact

Advanced Search

CME Courses
CME Webinars
Dialogues
Topics In Antiviral Medicine
HIV Drug Resistance
Fellow Resources
About

Gerald H. Friedland, MD

Gerald H. Friedland, MD

Professor Emeritus of Medicine and Epidemiology and Public Health

Yale University

New Haven, CT

131 Steuart St, Suite 500, San Francisco, CA 94105

Phone: (415) 544-9400 | info@iasusa.org

Home
Activities
Resources
About
Contact
Login
Careers
Donate
Website Policies

© 2025 International Antiviral Society–USA. All Rights Reserved.

CROI
Conference on Bacteriophages
RWHAP Clinical Conference
Podcasts
Key Slides
Question of the Week
Donate
Contact
CME Courses
CME Webinars
Dialogues
Topics In Antiviral Medicine
HIV Drug Resistance
Fellow Resources
About

Practice Question of the Week

January 20, 2025: Tirzepatide Dose and Weight Loss in a Person With HIV

A 52-year-old woman with HIV presents for routine follow-up care. She has an undetectable plasma HIV RNA level and currently takes aspirin 81 mg daily, rosuvastatin 20 mg daily, lisinopril 20 mg daily, and tirzepatide 10 mg weekly. Over the past 3 months, she has achieved 10% weight loss through a combination of lifestyle changes and medication support. Her current weight is 216 lb, with a body mass index of 34 kg/m2. Her last hemoglobin A1c level was 6.0%. She would like to achieve an additional 8% weight loss to reach a goal weight of 200 lb or lower. She experiences nausea after each weekly tirzepatide dose and has trouble eating 3 meals per day due to significant appetite suppression. Which of the following is the best response?
- A. Increase dose of tirzepatide to 12.5 mg weekly
- B. Start a combination of weight training and increased protein intake in her diet
- C. Recommend bariatric surgery
- D. Add metformin to her regimen
- E. Something else

Register for the Webinar

View Archived Questions